Nuvation Bio Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 75.8 million compared to USD 104.2 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.48 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | -2.08% | +3.45% | +118.54% |
05-14 | Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours | MT |
04-17 | RBC Raises Price Target on Nuvation Bio to $5 From $4, Keeps Outperform, Speculative Risk | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+118.54% | 885M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- NUVB Stock
- News Nuvation Bio Inc.
- Nuvation Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023